Actinium PharmaceuticalsATNM
Market Cap: 233M
About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Employees: 49
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
149% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $1.3M
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
79% more capital invested
Capital invested by funds: $29.2M [Q4 2023] → $52.1M (+$22.9M) [Q1 2024]
12% more funds holding
Funds holding: 58 [Q4 2023] → 65 (+7) [Q1 2024]
11.75% more ownership
Funds ownership: 12.22% [Q4 2023] → 23.97% (+11.75%) [Q1 2024]
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
Research analyst outlook
12 Wall Street Analysts provided 1 year price forecasts over the past 6 months
12 analyst ratings
HC Wainwright & Co. Joseph Pantginis | 539%upside $50 | Buy Reiterated | 26 Jul 2024 |
HC Wainwright & Co. Joseph Pantginis | 539%upside $50 | Buy Reiterated | 17 Jun 2024 |
HC Wainwright & Co. Joseph Pantginis | 539%upside $50 | Buy Reiterated | 21 May 2024 |
Stephens & Co. Sudan Loganathan | 220%upside $25 | Overweight Initiated | 14 May 2024 |
HC Wainwright & Co. Joseph Pantginis | 539%upside $50 | Buy Reiterated | 2 May 2024 |
Financial journalist opinion
Based on 5 articles about ATNM published over the past 30 days